Low-dose mTOR inhibition strongly attenuates immunosenescence, as demonstrated by clinical trials in old people: mTOR inhibition by either RAD001 monotherapy, or dual RAD001/BEZ235 therapy, improved influenza vaccination responses and decreased subsequent respiratory tract infection rates 1 year after treatment (Mannick et al., 2014; Mannick et al., 2018), while treatment with BEZ235 (also named RTB101) showed trends towards immune improvement (Mannick et al., 2021). Here, MTOR is linked to Respiratory tract infection.